{"id":"W2055922098","doi":"10.1158/1538-7445.am2011-4718","title":"Abstract 4718: A randomized phase 2 study of the cyclin-dependent kinase (CDK) inhibitor dinaciclib (SCH 727965) in patients with advanced breast cancer","year":2011,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Alberta Cancer Foundation","funders":"","keywords":"Capecitabine; Medicine; Internal medicine; Taxane; Anthracycline; Clinical endpoint; Febrile neutropenia; Neutropenia; Oncology; Breast cancer; Cancer; Chemotherapy; Randomized controlled trial; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002780527,0.001750386,0.002943209,0.0005631955,0.0004655446,0.0009188937,0.0006471648,0.00136129,0.009039531],"category_scores_gemma":[0.001930549,0.0009576411,0.001389338,0.0004016935,0.0009965759,0.0008816721,0.0005014796,0.002530608,0.001231517],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009609071,"about_ca_system_score_gemma":0.002072949,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007904374,"about_ca_topic_score_gemma":0.001881031,"domain_scores_codex":[0.9990302,0.0005757163,0.00004821397,0.0001364091,0.00006207,0.0001473268],"domain_scores_gemma":[0.9990733,0.0002380867,0.0001418368,0.00007827693,0.00005989538,0.0004085587],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9496395,0.02328997,0.001237567,0.0002585603,0.0003984897,0.00007716796,0.00005014854,0.000437105,0.004541589,0.000160686,0.001248493,0.01866068],"study_design_scores_gemma":[0.8716879,0.1254636,0.001114627,0.000009699274,0.0001407825,0.00002869068,0.00001147121,0.000352076,0.000297096,0.00008793006,0.0007957616,0.00001035424],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9750592,0.002020912,0.001213783,0.0007949943,0.0005565036,0.01592406,0.001796636,0.0001599894,0.00247391],"genre_scores_gemma":[0.9484977,0.002418285,0.005896065,0.003028095,0.0008757886,0.02911096,0.002899936,0.00006607814,0.007207089],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009039531,"threshold_uncertainty_score":0.03024024,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04744629479669468,"score_gpt":0.3890347226297202,"score_spread":0.3415884278330256,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}